170 related articles for article (PubMed ID: 18347114)
21. Metabolic engineering of aminocoumarins: inactivation of the methyltransferase gene cloP and generation of new clorobiocin derivatives in a heterologous host.
Freitag A; Rapp H; Heide L; Li SM
Chembiochem; 2005 Aug; 6(8):1411-8. PubMed ID: 15977275
[TBL] [Abstract][Full Text] [Related]
22. Resistance genes of aminocoumarin producers: two type II topoisomerase genes confer resistance against coumermycin A1 and clorobiocin.
Schmutz E; Mühlenweg A; Li SM; Heide L
Antimicrob Agents Chemother; 2003 Mar; 47(3):869-77. PubMed ID: 12604514
[TBL] [Abstract][Full Text] [Related]
23. Identification of 4-diphenylamino 3-iodo coumarin as a potent inhibitor of DNA gyrase B of S. aureus.
Sareena C; Vasu ST
Microb Pathog; 2020 Oct; 147():104387. PubMed ID: 32702375
[TBL] [Abstract][Full Text] [Related]
24. New aminocoumarin antibiotics from a cloQ-defective mutant of the clorobiocin producer Streptomyces roseochromogenes DS12.976.
Freitag A; Galm U; Li SM; Heide L
J Antibiot (Tokyo); 2004 Mar; 57(3):205-9. PubMed ID: 15152806
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, antimicrobial evaluation, DNA gyrase inhibition, and in silico pharmacokinetic studies of novel quinoline derivatives.
El-Shershaby MH; El-Gamal KM; Bayoumi AH; El-Adl K; Ahmed HEA; Abulkhair HS
Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000277. PubMed ID: 33078877
[TBL] [Abstract][Full Text] [Related]
26. Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors.
Jakopin Ž; Ilaš J; Barančoková M; Brvar M; Tammela P; Sollner Dolenc M; Tomašič T; Kikelj D
Eur J Med Chem; 2017 Apr; 130():171-184. PubMed ID: 28246042
[TBL] [Abstract][Full Text] [Related]
27. Novel topoisomerase inhibitors: microbiological characterisation and in vivo efficacy of pyrimidines.
Uria-Nickelsen M; Neckermann G; Sriram S; Andrews B; Manchester JI; Carcanague D; Stokes S; Hull KG
Int J Antimicrob Agents; 2013 Apr; 41(4):363-71. PubMed ID: 23305654
[TBL] [Abstract][Full Text] [Related]
28. Structure-activity relationship in two series of aminoalkyl substituted coumarin inhibitors of gyrase B.
Laurin P; Ferroud D; Schio L; Klich M; Dupuis-Hamelin C; Mauvais P; Lassaigne P; Bonnefoy A; Musicki B
Bioorg Med Chem Lett; 1999 Oct; 9(19):2875-80. PubMed ID: 10522710
[TBL] [Abstract][Full Text] [Related]
29. Structural and mechanistic analysis of ATPase inhibitors targeting mycobacterial DNA gyrase.
Henderson SR; Stevenson CEM; Malone B; Zholnerovych Y; Mitchenall LA; Pichowicz M; McGarry DH; Cooper IR; Charrier C; Salisbury AM; Lawson DM; Maxwell A
J Antimicrob Chemother; 2020 Oct; 75(10):2835-2842. PubMed ID: 32728686
[TBL] [Abstract][Full Text] [Related]
30. Effect of DNA gyrase inhibitors pefloxacin, five other quinolones, novobiocin, and clorobiocin on Escherichia coli topoisomerase I.
Tabary X; Moreau N; Dureuil C; Le Goffic F
Antimicrob Agents Chemother; 1987 Dec; 31(12):1925-8. PubMed ID: 2830840
[TBL] [Abstract][Full Text] [Related]
31. Synthesis, Antimicrobial Activity and Molecular Docking of Novel Thiourea Derivatives Tagged with Thiadiazole, Imidazole and Triazine Moieties as Potential DNA Gyrase and Topoisomerase IV Inhibitors.
Hashem HE; Amr AEE; Nossier ES; Elsayed EA; Azmy EM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32549386
[TBL] [Abstract][Full Text] [Related]
32. Mechanism of inhibition of DNA gyrase by cyclothialidine, a novel DNA gyrase inhibitor.
Nakada N; Gmünder H; Hirata T; Arisawa M
Antimicrob Agents Chemother; 1994 Sep; 38(9):1966-73. PubMed ID: 7811004
[TBL] [Abstract][Full Text] [Related]
33. Mannich reaction derivatives of novobiocin with modulated physiochemical properties and their antibacterial activities.
Tambo-ong A; Chopra S; Glaser BT; Matsuyama K; Tran T; Madrid PB
Bioorg Med Chem Lett; 2011 Oct; 21(19):5697-700. PubMed ID: 21871799
[TBL] [Abstract][Full Text] [Related]
34. Discrepancy between the antibacterial activities and the inhibitory effects on Micrococcus luteus DNA gyrase of 13 quinolones.
Fu KP; Grace ME; McCloud SJ; Gregory FJ; Hung PP
Chemotherapy; 1986; 32(6):494-8. PubMed ID: 3026740
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of DNA gyrase inhibitors, singly and in combination, against Mycobacterium avium complex.
Babinchak TJ; Fass RJ
Diagn Microbiol Infect Dis; 1992; 15(4):367-70. PubMed ID: 1319302
[TBL] [Abstract][Full Text] [Related]
36. Gyrase inhibitors can increase gyrA expression and DNA supercoiling.
Franco RJ; Drlica K
J Bacteriol; 1989 Dec; 171(12):6573-9. PubMed ID: 2556367
[TBL] [Abstract][Full Text] [Related]
37. In vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases.
Charrier C; Salisbury AM; Savage VJ; Moyo E; Forward H; Ooi N; Cheung J; Metzger R; McGarry D; Walker R; Cooper IR; Ratcliffe AJ; Stokes NR
J Antimicrob Chemother; 2016 Oct; 71(10):2831-9. PubMed ID: 27353465
[TBL] [Abstract][Full Text] [Related]
38. Chemoenzymatic formation of novel aminocoumarin antibiotics by the enzymes CouN1 and CouN7.
Fridman M; Balibar CJ; Lupoli T; Kahne D; Walsh CT; Garneau-Tsodikova S
Biochemistry; 2007 Jul; 46(28):8462-71. PubMed ID: 17580964
[TBL] [Abstract][Full Text] [Related]
39. Characterization of the aminocoumarin ligase SimL from the simocyclinone pathway and tandem incubation with NovM,P,N from the novobiocin pathway.
Pacholec M; Freel Meyers CL; Oberthür M; Kahne D; Walsh CT
Biochemistry; 2005 Mar; 44(12):4949-56. PubMed ID: 15779922
[TBL] [Abstract][Full Text] [Related]
40. New aminocoumarin antibiotics from genetically engineered Streptomyces strains.
Li SM; Heide L
Curr Med Chem; 2005; 12(4):419-27. PubMed ID: 15720250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
